Many of the anti-breast cancer agents listed above (anthracycline, HER2 agents, cyclophosphamide, Immune Checkpoint Inhibitors) are associated with ventricular systolic failure, and clinically this is the most common clinically encountered cardio-oncology referral [4]. The gene discussed is ERBB2; the disease is breast cancer.